Nanobody against PDL1

• DOI: 10.1007/s10529-020-02823-2
• Publication Date: 2020-01-31T14:02:41Z
• Authors: Shufeng Li; Kunpeng Jiang; Ting Wang; Wei Zhang; Minke Shi; Baojun Chen; Zichun Hua
• Keywords: 0301 basic medicine; Camelus; Programmed Cell Death 1 Receptor; Single-Domain Antibodies; B7-H1 Antigen; 3. Good health; 03 medical and health sciences; HEK293 Cells; Neoplasms; Animals; Humans; Immunization; Tumor Escape; Cell Surface Display Techniques

Programmed death ligand 1 (PDL1, CD274, B7-H1) has been identified as the ligand for the immune inhibitory receptor programmed death 1 protein (PD1/PDCD1). PDL1 is a member of B7 family of immune molecules and this protein together with PDL2, are two ligands for PD1 expressed on activated lymphoid cells. By binding to PD1 on activated T cells, PDL1 may inhibit T cell responses by inducing apoptosis. Accordingly, it leads to the immune evasion of cancers and contribute to tumor growth, thus PDL1 is regarded as therapeutic target for malignant cancers. We selected PDL1 specific nanobodies from a high quality dromedary camel immune library by phage display technology, three anti-PDL1-VHHs were developed.